Supportively, PAK4 inhibition reversed the cisplatin resistance of non-small cell lung cancer cells [30] and sensitized pancreatic cancer cells to gemcitabine and multiple chemotherapeutic agents [31,32]. Here, PAK4 is linked to pancreatic neoplasm.